243 filings
Page 11 of 13
8-K
08t3 0wl9
11 Jan 21
Regulation FD Disclosure
6:03am
8-K
q22tid0
8 Jan 21
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
10:53am
8-K
vg2sktgkyu
6 Jan 21
InMed to Participate at Virtual Conferences in January 2021
12:00am
10-Q
86wv5ieecxd5wep1
17 Dec 20
Quarterly report
12:00am
8-K
ph30va
4 Dec 20
Departure of Directors or Certain Officers
1:48pm
8-K
ts59otklkxhr8
3 Dec 20
Regulation FD Disclosure
12:59pm
8-K
2ufr1ysfppvo6blfa6
25 Nov 20
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755
10:47am
8-K
nzip9bpo
25 Nov 20
InMed Announces Election of Directors
12:00am
8-K
25pr6
18 Nov 20
Regulation FD Disclosure
12:31pm
8-K
0l94n3c17ieu8 5mwj
16 Nov 20
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
3:00pm
424B4
woc v5pyqo6d
13 Nov 20
Prospectus supplement with pricing info
8:52pm
8-K
ab1sbug g9
13 Nov 20
InMed Pharmaceuticals Reports First Quarter Fiscal
1:19pm
EFFECT
vd49lpbz
13 Nov 20
Notice of effectiveness
12:15am
8-K
9sce4
12 Nov 20
InMed Announces Pricing of US$8M Public Offering and
10:15am
CORRESP
ragtmoy5u 96epel0
10 Nov 20
Correspondence with SEC
12:00am
CORRESP
7n50u7v0rom3
10 Nov 20
Correspondence with SEC
12:00am
CORRESP
1jd8kq47 9f
10 Nov 20
Correspondence with SEC
12:00am
CERT
yay3a6i h5
6 Nov 20
Certification of approval for exchange listing
11:19am
8-A12B
c2gn mojlr
5 Nov 20
Registration of securities on exchange
12:00am
CORRESP
ojd e8hc7t
5 Nov 20
Correspondence with SEC
12:00am